

ASX RELEASE

26 AUGUST 2025

## AMPLIA SHARE PURCHASE PLAN RAISES A\$2.65 MILLION

### HIGHLIGHTS

- *Share Purchase Plan (SPP) closed on Friday, 22 August 2025 with valid applications received for A\$2.65 million of New Shares, exceeding the original target of A\$2.5 million.*
- *New Shares issued under the SPP will be priced at \$0.18 each (SPP Offer Price).*
- *The SPP and institutional placement announced on 23 July 2025 will raise a total of \$27.65 million (the **Capital Raising**).*
- *The proceeds of the Capital Raising will:*
  - *support the ACCENT and AMPLICITY trials, and support potential investigator initiated trials, of the Company's lead drug narmafotinib (AMP945); and*
  - *enable Amplia to accelerate towards commencement of a potential pivotal phase 2b/3 trial for AMP945 in 2H 2026.*
- *Following the Capital Raising the Company will be funded into 2027.*
- *Completion of the SPP is subject to shareholder approval at the Annual General Meeting on Wednesday 27 August 2025.*

**Melbourne, Australia:** Amplia Therapeutics Limited (ASX: ATX), (**Amplia** or the **Company**), is pleased to announce that its SPP closed on Friday, 22 August 2025 with valid applications received for A\$2.65 million worth of New Shares. This exceeds the original target of A\$2.5 million.

The SPP was announced on 23 July 2025 as part of a Capital Raising comprising:

- A placement of ~96.8 million new, fully paid ordinary shares (**New Shares**) at an offer price of \$0.23 per New Share (**Placement Offer Price**) to raise A\$22.3 million utilising its available capacity under ASX Listing Rules 7.1 and 7.1A (**Unconditional Placement**). The Unconditional Placement completed on 29 July 2025.
- A placement of ~10.9 million New Shares at the Placement Offer Price (\$0.23) to raise A\$2.5 million, conditional on shareholder approval for the purposes of ASX Listing Rule 7.1 (**Conditional Placement**). Approval is being sought for the Conditional Placement at the 2025 Annual General Meeting (on Wednesday, 27 August 2025).
- A placement of ~1.0 million New Shares at the Placement Offer Price (\$0.23) to the Amplia Directors, conditional on shareholder approval for the purposes of ASX Listing Rule 10.11 (**Director Placement**). Approval is being sought for the Director Placement at the 2025 Annual General Meeting.
- The share purchase plan, which was seeking to raise up to \$2.5 million, with the ability to accept oversubscriptions of up to an additional \$7.5 million (**SPP**). The SPP was undertaken pursuant to a prospectus dated 1 August 2025.

The SPP was undertaken at the **SPP Offer Price**, being the lower of:

- the Placement Offer Price (of \$0.23); and
- the price representing a 5.0% discount to the volume weighted average price of Amplia shares traded during the 5 trading days up to and including the SPP Closing Date, rounded to the nearest half cent.

The volume weighted average price of Shares traded during the five trading days up to and including the Closing Date (of Friday 22 August 2025) was \$0.190, and accordingly the SPP Offer Price will be \$0.18 per New Share.

As a result, a total of 14,703,299 New Shares will be issued under the SPP and there will be no scale-back in applications.

Commenting on the successful Share Purchase Plan, Amplia Managing Director Dr Chris Burns commented: "We are extremely grateful for the support from existing shareholders in this SPP. The funds from the SPP will support our ongoing clinical studies, along with planning for follow-on trials, to build on the exciting data already obtained for narmafotinib in the ACCENT study in pancreatic cancer."

The SPP is conditional on Amplia shareholder approval for the purposes of Listing Rule 7.1 at the Company's AGM which will be held Wednesday, 27 August 2025.

Assuming shareholder approval is confirmed at the AGM, the issue of New Shares under the SPP will occur on Friday, 29 August 2025 and normal trading on the ASX will commence on Monday, 1 September 2025.

The Board has determined that it will not seek to place any SPP Shortfall Shares and accordingly it will not undertake the 'SPP Shortfall Offer' as contemplated in the SPP prospectus.

#### **Other Information**

Further information about the Capital Raise, including the SPP and the Company can be found in the presentation lodged with ASX on 22 July 2025, which is available on the ASX's website ([www.asx.com.au](http://www.asx.com.au)) and the Company's website ([www.ampliatx.com](http://www.ampliatx.com)).

This ASX announcement was approved and authorised for release by the Board of Amplia Therapeutics Limited.

#### **Investor Contact:**

Dr Chris Burns  
Chief Executive Officer  
[chris@ampliatx.com](mailto:chris@ampliatx.com)

#### **Media Contact:**

HACK Director, Haley Chartres  
[haley@hck.digital](mailto:haley@hck.digital)  
+61 423 139 163

#### **About Amplia Therapeutics Limited**

Amplia Therapeutics Limited is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. FAK is an increasingly important target in the field of cancer and Amplia has a particular development focus in fibrotic cancers such as pancreatic

and ovarian cancer. FAK also plays a significant role in a number of chronic diseases, such as idiopathic pulmonary fibrosis (IPF). For more information visit [www.ampliatx.com](http://www.ampliatx.com) and follow Amplia on [Twitter](https://twitter.com/ampliatx) (@ampliatx), and [LinkedIn](https://www.linkedin.com/company/amplia).

#### **IMPORTANT INFORMATION**

This announcement has been prepared for publication in Australia and may not be released to U.S. wire services or distributed in the United States. This announcement does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States or any other jurisdiction. Any securities described in this announcement have not been, and will not be, registered under the U.S. Securities Act of 1933 and may not be offered or sold in the United States except in transactions exempt from, or not subject to, registration under the U.S. Securities Act and applicable U.S. state securities laws.

For personal use only